美服培酮/米索前列醇
美服培酮/米索前列醇是包括两种成分的单一复方药物,主要用于药物流产[7]。这是怀孕11 周以内的常用堕胎方法之一,但也可在怀孕中期使用[3] [9]。也可治疗 12 周以内的早期流产[3]。可以利用妊娠试验或超声波检查确认妊娠是否成功[3]。可以口服或舌下服用[7] [10]。在怀孕前期,通常可以在家中自行使用,可以由家庭医师直接就诊时或透过远距医疗开立处方;若在妊娠中期,建议住院处理[3] [9]。
组成 | |
---|---|
美服培酮 | 孕激素受体拮抗剂 |
米索前列醇 | Prostaglandin E1 |
临床资料 | |
商品名 | Mifegymiso,[1] Medabon Combipack,[2] others |
给药途径 | 口服、阴道塞剂[3] |
法律规范状态 | |
法律规范 |
|
副作用包括可能恶心、腹痛和轻度发热[3]。可能出现子宫痉挛和阴道出血[3]。大量出血、持续妊娠和感染则较罕见[3]。它不会增加精神障碍、乳癌或不孕的风险[3]。药物含有美服培酮和米索前列醇,前者是一种抗孕激素,会使蜕膜分解,后者是一种前列腺素 E1 ,会促使宫颈成熟和子宫收缩[3]。
美服培酮于 1987 年在法国开始使用,美国则始于 2000 年[11] [12]。此成分的学名药在 2019 年上市[12]。米索前列醇于 1973 年研发成功[13]。美服培酮/米索前列醇的复方药名列世界卫生组织基本药物标准清单[14]。
参考文献
编辑- ^ Linepharma International Limited. Mifegymiso Product Monograph (PDF). Health Canada. 15 April 2019 [10 September 2023]. (原始内容存档 (PDF)于22 March 2023). 互联网档案馆的存档,存档日期22 March 2023.
- ^ Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). 3 February 2020 [19 January 2021]. (原始内容存档于9 June 2021). 互联网档案馆的存档,存档日期9 June 2021.
- ^ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 Macnaughton, H; Nothnagle, M; Early, J. Mifepristone and Misoprostol for Early Pregnancy Loss and Medication Abortion.. American family physician. 15 April 2021, 103 (8): 473–480 [6 December 2023]. PMID 33856168. (原始内容存档于19 October 2023). 互联网档案馆的存档,存档日期19 October 2023.
- ^ Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). 3 February 2020 [19 January 2021]. (原始内容存档于9 June 2021). 互联网档案馆的存档,存档日期9 June 2021.
- ^ The Abortion Pill | Get the Facts About Medication Abortion. Planned Parenthood. [2023-08-18]. (原始内容存档于2023-08-16). 互联网档案馆的存档,存档日期2023-08-16.
- ^ Mifepristone/misoprostol: List of nationally authorised medicinal products (PDF). European Medicines Agency. 14 January 2021 [18 August 2023]. PSUSA/00010378/202005. (原始内容存档 (PDF)于16 September 2023). 互联网档案馆的存档,存档日期16 September 2023.
- ^ 7.0 7.1 7.2 eEML - Electronic Essential Medicines List. list.essentialmeds.org. [8 September 2023]. (原始内容存档于4 June 2023).
- ^ 8.0 8.1 Mifepristone and misoprostol: Recommended regimen. Ipas. [10 September 2023]. (原始内容存档于22 April 2023). 互联网档案馆的存档,存档日期22 April 2023.
- ^ 9.0 9.1 Gemzell-Danielsson, K; Lalitkumar, S. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management.. Reproductive health matters. May 2008, 16 (31 Suppl): 162-72. PMID 18772097. doi:10.1016/S0968-8080(08)31371-8.
- ^ Zhang J, Zhou K, Shan D, Luo X. Medical methods for first trimester abortion. The Cochrane Database of Systematic Reviews. May 2022, 2022 (5): CD002855. PMC 9128719 . PMID 35608608. doi:10.1002/14651858.CD002855.pub5.
- ^ Corey, E.J. https://web.archive.org/web/20170908184336/https://books.google.com/books?id=jz2GN6DYoOoC&pg=RA1-PT108
|archiveurl=
缺少标题 (帮助). Mifepristone. John Wiley & Sons. 2012. ISBN 9781118361733. (原始内容存档于2017-09-08). - ^ 12.0 12.1 Research, Center for Drug Evaluation and. Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation. FDA. 24 March 2023 [10 September 2023]. (原始内容存档于21 April 2023) (英语).
- ^ Paul, Maureen. https://web.archive.org/web/20151222100701/https://books.google.ca/books?id=iK7xrRr2p9sC&pg=RA1-PT161
|archiveurl=
缺少标题 (帮助). Misoprostol. John Wiley & Sons. 2011 [20 December 2015]. ISBN 9781444358476. (原始内容存档于22 December 2015). - ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.